SHARE

Earth Science Tech Inc (OTCMKTS:ETST) has announced that it would be focusing its R&D efforts towards the development of three new advanced CBD nutraceutical products, as well as two CBD-based pharmaceutical drugs. The company also noted that it would be utilizing its patent for cannabis CBD, its IPs and current and future technologies, on these projects. ETST also announced that the project would be initiated in Canada, through a joint venture, which is yet to be finalized.

Providing details about the venture, the company revealed that it would provide them with access to state-of-the-art laboratories, to further develop these drugs, for the alleviation of certain disorders and conditions. In addition to this, Earth Science revealed that it plans to target only those diseases, for which the benefits of CBD are already known.

In particular, the new products would be focused on breast cancer, improvement in human brain cell function and improvements in immune cell functions. It should be noted here that the company has already conducted an in vitro study, which proves the effectiveness of CBD for the stated conditions. Moreover, ETST also has a provisional patent application pending, with regards to this study. The CEO and CSO of Earth Science, Dr. Michel Aube, claimed that the drugs would treat a number of diseases, which include depression, anxiety, fatty liver disease and triple-negative breast cancer. He further voiced his belief that this represents a large market for the products and he was looking forward to discuss further details of the project.

The CEO also reaffirmed that ETST has access to the laboratory resources and scientific researchers needed for the development of these products. He also claimed that the move would help the company solidify its position in the cannabis market. Dr. Aube also stated that the two new CBD-based pharmaceutical drugs would help them enter a whole new market.

Earth Science Tech Inc (OTCMKTS:ETST) recorded a trade volume of 5,050 and a gain of 26.3% in terms of its share value, during the December 20 trading session, to close at $0.379 per share.

SHARE
Previous articleOncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a Huge Bounce Candidate in Multi-Billion Dollar Prostate Cancer Market
Next articleLeo Motors Inc. (OTCMKTS:LEOM) Finalizes $300 Million Sales Contract
Steve Kanaval
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.